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Background: This review aims to determine if patients who undergo atrial fibrillation (AF) ablation with
heart failure with preserved ejection fraction (HFpEF) do better, or worse or the same compared to
patients with heart failure with reduced ejection fraction (HFrEF).
Methods: A search of MEDLINE and EMBASE was performed using the search terms: “atrial fibrillation”,
“ablation” and terms related to HFpEF and HFrEF in order to identify studies that evaluated one or more
of i) AF recurrence, ii) periprocedural complications and iii) adverse outcomes at follow up for patients
with HFpEF and HFrEF who underwent AF ablation. Data was extracted from included studies and sta-
tistically pooled to evaluate adverse events and AF recurrence.
Results: 5 studies were included in this review and the sample size of the studies ranged from 91 to 521
patients with heart failure. There was no significant difference in the pooled rate for no AF or symptom
recurrence after AF ablation comparing patients with HFpEF vs HFrEF (RR 1.07 95%CI 0.86e1.33, p ¼ 0.15).
The most common complications were access site complications/haematoma/bleeding which occurred in
similar proportion in each group; HFpEF (3.1%) and HFrEF (3.1%). In terms of repeat ablations, two studies
were pooled to yield a rate of 78/455 (17.1%) for HFpEF vs 24/279 (8.6%) for HFrEF (p ¼ 0.001.
Conclusions: Heart failure patients with preserved or reduced ejection fraction have similar risk of AF or
symptom recurrence after AF ablation but two studies suggest that patients with HFpEF are more likely
to have repeat ablations.
Copyright © 2021, Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atrial fibrillation (AF) is one of the most common arrhythmias
which affects 1 in 200 patients in the adult population [1]. It is
important because it can lead to undesirable symptoms and serious
complications such as embolic stroke [2]. Both American and Eu-
ropean guidelines endorse either a rate or rhythm control strategy
where the former uses negative chronotropic medications and
anticoagulation to reduce stroke risk while the latter includesital, Newcastle Rd, Stoke-on-
wok).
Rhythm Society.
ociety. Production and hosting by
ok, A. Morley-Davies et al., A
r reduced left ventricular fu
.1016/j.ipej.2021.09.002electrical and chemical cardioversion including AF ablation to
achieve rhythm control [3,4]. It is not clear that all heart failure
patients with AF will benefit from AF ablation. While it is recog-
nized that many patients with heart failure (HF) are comorbid and
frail thus increasing their risk of complications from invasive pro-
cedures, the CASTLE AF suggested that patients with heart failure
with poor left ventricular function have prognostic gain AF ablation
[5].
Despite both conditions having similar presentations, the
pathophysiology of heart failure with preserved ejection fraction
(HFpEF) is very different from heart failure with reduced ejection
fraction (HFrEF) which may affect the likelihood of success with AF
ablation. In HFrEF there is a failure of left ventricular contraction
due to a number of pathologies such as myocardial infarction or
cardiomyopathy while in HFpEF the left ventricular contraction is
preserved but the stiffness of the ventricle impairs the relaxationElsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
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nction: A systematic review and meta-analysis, Indian Pacing and
Fig. 1. Flow diagram of study selection.
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have been reported to be valvular AF and larger left atrial diameter
(>5 cm) [8]. It has been suggested that the HFrEF is associated with
increased left atrial diameter [9]. However, patients with HFpEF
undergo atrial remodelling which results in increases left atrial
pressure and left atrial volume [10]. The increase in left atrial vol-
ume is a strong predictor of the recurrence after ablation because of
its link to fibrosis and a reduction in atrial wall compliance [11]. It is
currently unknown whether the patients who undergo AF ablation
with HF and preserved ejection fraction do better, or worse or the
same compared to patients with HF reduced ejection fraction.
We, therefore, conducted a systematic review andmeta-analysis
of studies which compared outcomes in patients with HFpEF and
HFrEF who undergo AF ablation. The primary outcome of interest
was in AF recurrence but we were also interested in the potential
differences in baseline characteristics, periprocedural complica-
tions and long-term adverse events.
2. Methods
The reporting of this systematic review is in according to the
recommendations of the MOOSE checklist [12] (Supplementary
Table 1).
2.1. Eligibility criteria
We selected parallel-group studies that evaluated one or more
of i) AF recurrence, ii) periprocedural complications and iii) adverse
outcomes at follow up for patients with HFpEF and HFrEF who
underwent AF ablation. We included all studies irrespective of
design (retrospective or prospective), mode of presentation (i.e.,
conference abstract) or language of publication. We excluded
studies without original data including reviews, editorials and
commentaries.
2.2. Search strategy
We searched the OVID platform to identify studies in Embase
and MEDLINE was between 1974 to 2020 and 1946 to 2020,2
respectively. The search terms used were: (“atrial fibrillation”) AND
(“ablation”) AND (“heart failure with preserved ejection fraction”
OR “HFpEF” OR “heart failure with reduced ejection fraction” OR
“HFrEF”). We also checked the bibliographies of included studies
and relevant reviews for additional studies.
2.3. Study selection and data extraction
Two reviewers (GP and CSK) independently and in duplicate
assessed the titles and abstracts of the search results and excluded
studies that were not relevant. Full-text of potentially relevant
studies were retrieved and a detailed review was performed
against the eligibility criteria. Any uncertainties about inclusion
were resolved by consensus through discussion with other co-
authors after a full review of the manuscript. The primary
outcomewas to assess recurrence of AF or recurrence of symptoms.
The secondary outcomes included periprocedural complications,
adverse cardiovascular events, hospitalization, repeat ablations and
mortality.
2.4. Study characteristics and quality assessment
Two reviewers (GP and CSK) independently extracted data on
study characteristics. We recorded data on study design, country,
years of study, total number of participants, mean age, % of male
participants, participant inclusion criteria, patient demographic
variables, comorbidities, medications, definition of heart failure,
type of AF, method of AF ablation, follow up and outcome according
to HFpEF or HFrEF. Both crude event rates andmost adjusted results
were extracted.
Study quality was evaluated by considering risk of bias using the
Newcastle-Ottawa Scale for cohort studies [13]. Funnel plots were
used to evaluated publication bias if the analysis had more than 10
included studies and no evidence of statistical heterogeneity [14].
2.5. Data synthesis
Data was collected and presented in tables. Results for peri-
procedural complication and long term adverse events were pooled
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primary outcome of a good outcome after AF ablation (no recur-
rence of AF, no symptoms or clinical success), we used RevMan 5.3
(The Nordic Cochrane Centre) to conduct random-effects meta-
analysis for the pooled relative risks (RR), with 95% confidence
intervals based on the inverse variance method. Statistical hetero-
geneity was assessed using the I2 statistic where 30e60% represent
a moderate level of heterogeneity [16].3. Results
3.1. Study selection
A total of 5 studies were included in this review after screening
and reviewing potentially relevant studies in detail (Fig. 1) [17e24].3.2. Study design and patient characteristics
The description of the study design, patient characteristics and
study inclusion criteria is shown in Table 1. There were 4 retro-
spective cohort studies and 1 prospective cohort study and these
studies took place in the USA, Germany, Czech Republic and Japan.
The sample size of the study ranged from 91 to 521 patients with
heart failure. There were a total 634 patients with HFpEF and 417
patients with HFrEF in the 5 studies which reported proportion of
patients with HFpEF and HFrEF. The mean age of the participants
ranged from 62.0 to 65.3 years from 3 studies and the percentage of
male patients ranged from 68.7% to 80.2%. The average mean age
and proportion of male patients (±2SD) across the studies that
reported these figures were 63.3 ± 3.5 years and 72.1 ± 10.9%. The
average age across the studies was numerically higher among pa-
tients in the group with HFpEF compared to HFrEF (64.1 years vs
62.3 years, p ¼ 0.35) but the average proportion of male patients
was higher in the group with HFrEF (66.2% vs 80.4%, p ¼ 0.06). The
follow up and procedure related data are summarized in Table 2.
The comparison of patient characteristics for HFpEF and HFrEF is
shown in Supplementary Table 2. Among the studies, there was no
pattern to suggest that patients with HFrEF were older compared to
those with HFpEF but patients with HFrEF appeared to have a
greater proportion of patients that were male. The average pro-
portion of patients with hypertension (74.2% vs 66.9%, p ¼ 0.18),
hyperlipidaemia (51.0% vs 49.0%), diabetes mellitus (19.9% vs 16.2%,
p ¼ 0.24) and use of b-blockers (67.5% vs 69.3%, p ¼ 0.42) and
angiotensin converting enzyme inhibitors (42.7% vs 50.8%,
p ¼ 0.26) were not statistically different for patients with HFpEF
and HFrEF. The proportion of male patients was greater amongTable 1
Study design, patient characteristics and inclusion criteria.
Study ID Study design; Country; Year Total participants Mean age
Aldaas
2020
Retrospective cohort study; USA;
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HFpEF ¼ heart failure with preserved ejection fraction, HFrEF ¼ heart failure with red
USA¼United States of America, LVEF ¼ left ventricular ejection fraction.
3
patients with HFrEF compared to HFpEF (80.1% vs 65.0%, p < 0.001)
(Supplementary Table 3).
3.3. Definitions for heart failure and atrial fibrillation
The definitions of heart failure, AF and description of AF ablation
procedure are shown in Supplementary Tables 4 and 5 Different
cutoffs for ejection fraction was used to define patients with HFpEF
and HFrEF as some studies used 50%, 45% and 40% with others
including a heart failure with mid-range ejection fraction. Most
studies included a combination of permanent and paroxysmal AF. A
variety of methods were used to carry out the ablation along with
different anatomical sites for ablation.
3.4. Study quality assessment
The quality assessment of the included studies is shown in
Supplementary Table 6. Aside from demonstration that the
outcome of interest was not present at the start of the study, all of
the studies had reliable criteria for representativeness of cohort,
selection of non-exposed cohort, ascertainment of exposure,
comparability of the cohorts, assessment of outcome and adequacy
and length of follow up for the cohorts.
3.5. Outcomes according to HFpEF and HFrEF
The pooled risk of atrial fibrillation recurrence or no recurrence
of symptoms in patients who underwent ablation showed no sig-
nificant difference for HFpEF vs HFrEF (RR 1.07 95%CI 0.86e1.33,
p ¼ 0.15, I2 ¼ 38%) (Fig. 2).
The detailed descriptive data for the included studies are shown
in Supplementary Tables 7, 8 and 9. The pooled results for adverse
periprocedural events are shown in Table 3. The most common
complications were access site complications/haematoma/
bleeding, which occurred equally in patients with HFpEF (3.1%)
compared to HFrEF (3.1%) (p ¼ 1.0). Other complications that
appear in less than 1% of patients included stroke/transient
ischaemic attack, cardiac perforation/tamponade, death and major
adverse cardiovascular events.
The pooled follow up events are shown in Table 4. In terms of
repeat ablations, two studies (Black-Meier 2018 and Eitel 2020)
were pooled to yield a rate of 78/455 (17.1%) for HFpEF vs 24/279
(8.6%) for HFrEF (p ¼ 0.001) and one study (Black-Meier 2018) re-
ported the rate of arrhythmic hospitalization of 19/133 (14.3%) for
HFpEF vs 13/97 (13.4%) for HFrEF (p ¼ 0.85). In Eitel et al., one-year









68.7 Patients with AF ablation at the Duke Center for Atrial fibrillation.
70.3 Patients aged 18 years or older in the German ablation registry with
NYHA class II and symptomatic AF.
e Patients with AF ablation and NYHA class II at a single centre in
Prague, Czech Republic.
80.2 Patients with AF and heart failure who underwent ablation in a
centre in Tsuchiura, Japan.
uced ejection fraction, AF ¼ atrial fibrillation, NYHA¼New York Heart Association,
Table 2
Follow up and outcomes for HFpEF vs HFrEF.
Study ID Duration of follow up Outcomes for HFpEF vs HFrEF
Aldaas 2020 Median: HFpEF 50.9 months
HFrEF 24.2 months
Median procedure time: 277 vs 266 min
Median fluoroscopy time: 73 vs 84 min
Access site complication: 5/51 vs 6/40
Cardiac perforation/tamponade: 1/51 vs 0/40
Stroke/TIA: 0/51 vs 0/40
Pericarditis: 1/51 vs 0/40
Adjusted hazards of adverse outcomes for HFpEF vs HFrEF:
Recurrence of AF/AFL/AT on or off AAD: aHR 1.92 (0.97e3.83)
Recurrence of AF/AFL/AT off AAD: aHR 2.52 (0.73e8.77)
All-cause hospitalizations: aHR 1.80 (0.97e3.33)
All-cause mortality: aHR 0.53 (0.05e6.11)
Black-Meier 2018 Median: HFpEF 10.3 months, HFrEF 10.6 months Median procedure time: 233 vs 233.5 min
Median fluoroscopy time: 58.6 vs 57.1 min
Access site bleeding: 4/133 vs 4/97
Stroke/TIA: 0/133 vs 4/97
Acute HF: 5/133 vs 6/97
ECG recurrence: 43/133 vs 31/97
AAD class IC/III use at 12 months: 71/133 vs 46/97
Repeat ablation: 6/133 vs 3/97
All-cause hospitalizations at 12 months: 28/133 vs 31/97
Cardiovascular hospitalization at 12 months: 28/133 vs 22/97
HF hospitalization at 12 months: 8/133 vs 10/97
Arrhythmia hospitalization at 12 months: 19/133 vs 13/97
Adjusted hazards of recurrence by AF type for HFpEF vs HFrEF:
Paroxysmal AF: aHR 2.04 (0.41e10.07)
Persistent AF: aHR 1.38 (0.53e3.60)
Eitel 2020 12 months follow up was 97% for HFpEF and 97.3% for
HFrEF
Fluoroscopy time: 30.5 ± 23.7 vs 26.6 ± 25.8
Procedure duration: 175.8 ± 77.8 vs 122.9 ± 81.1
Death: 0/338 vs 1/188
MACE (death, MI): 0/338 vs 1/188
MACCE (death, MI, stroke): 2/338 vs 1/188
Stroke: 2/338 vs 0/188
Major bleeding: 7/338 vs 0/188
Transient ischaemic attack: 2/338 vs 1/188
Cardiac tamponade: 2/338 vs 2/188
Aneurysm spurium, arteriovenous fistula: 8/338 vs 0/188
Atrio-osophageal fistula: 0/338 vs 0/188
Minor bleeding: 20/338 vs 0/188
Duration of hospital stay: 4 [3,6] vs 4 [2,7] days
Follow up data:
No symptoms: 61/322 vs 22/182
Rehospitalisation: 150/322 vs 68/182
Re-ablation: 72/322 vs 21/182
1-year mortality: 1.9% (6/322) vs 6.1% (11/182)
Non-fatal MI: 0/322 vs 1/182
Non-fatal stroke: 4/322 vs 1/182
Major bleeding: 1/322 vs 3/182
Transient ischaemic attack: 2/322 vs 0/182
Havranek 2020 Mean follow up: 43 months Radiofrequency time: 53 ± 22 vs 63 ± 26 min
Procedural time: 250 ± 75 vs 254 ± 68 min
Good rhythm control without AAD: 26/62 vs 10/41
Good rhythm control ± AAD: 47/62 vs 27/41
Ichijo 2018 Mean follow up:
HFpEF 32.8 months HFrEF 32.0 months
Procedural complications (cardiac tamponade, air embolism phrenic nerve injury): 3/55
vs 1/51
Free from any recurrent arrhythmias: 47/55 vs 47/51
Arrhythmia-free survival at 4 years: 79.3% (44/55) vs 88.7% (45/51)
Heart failure related hospitalization at 4 years: 96.2% (53/55) vs 97.6% (50/51)
Freedom from composite endpoint at 4 years: 91.8% (50/55) vs 88.7% (45/51)
HFpEF¼ heart failure with preserved ejection fraction, HFrEF¼ heart failure with reduced ejection fraction, TIA¼ transient ischemic attack, AF¼ atrial fibrillation, AFL¼ atrial
flutter, AT ¼ atrial tachycardia, AAD ¼ anti-arrhythmic drug, MACE ¼ major adverse cardiac event, MACCE ¼ major adverse cardiac and cerebrovascular events,
MI ¼ myocardial Infarction, aHR ¼ adjusted hazard ratio.
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no significant difference after adjustments (aHR 0.53 95%CI
0.05e6.11). There were no significant differences in all-cause hos-
pitalizations (p ¼ 0.33), stroke/TIA (p ¼ 0.59), heart failure hospi-
talizations (p ¼ 0.23), arrhythmia hospitalizations (p ¼ 0.85) non-
fatal myocardial infarction (p ¼ 0.20) and major bleeding
(p ¼ 0.11) comparing HFpEF to HFrEF.4
4. Discussion
We have conducted this systematic review of 5 studies with
total 1051 patients and the main findings of our study are no sig-
nificant difference in AF recurrence and secondary outcomes of
adverse events for patients undergoing AF ablation with regard to
the type of heart failure syndrome based on their left ventricular
function.
Fig. 2. Meta-analysis of atrial fibrillation recurrence or good outcome for patients with HFpEF vs HFrEF who undergo atrial fibrillation ablation*.
Table 3
Pooled results for periprocedural adverse events.
Outcome No. studies HFpEF HFrEF p-value
Access site complication/haematoma/bleeding 3 3.1% (16/522) 3.1% (10/325) 1.00
Stroke/TIA 2 0.7% (4/587) 0.2% (1/426) 0.26
Cardiac perforation/tamponade 2 0.8% (3/389) 0.9% (2/228) 0.19
Death 1 0% (0/338) 0.9% (2/228) 0.009
Pericarditis 1 2.0% (1/51) 0% (0/40) 0.53
MACCE (death, MI, stroke) 1 0.6% (2/338) 0.5% (1/188) 0.39
HFpEF ¼ heart failure with preserved ejection fraction, HFrEF ¼ heart failure with reduced ejection fraction, TIA ¼ transient ischaemic attack, MACCE ¼major adverse cardiac
and cerebrovascular event, MI ¼ myocardial infarction.
Table 4
Follow up adverse events.
Outcome No. studies HFpEF HFrEF p-value
1-year mortality (Eitel et al.) 1 1.9% (6/322) 6.0% (11/182) <0.001
Adjusted HR (Aldaas et al.) aHR 0.53 (0.05e6.11) 1
All-cause hospitalization (Aldaas et al., Eitel et al.) 2 39.1% (178/455) 35.5% (99/279) 0.33
Adjusted HR (Aldaas et al.) aHR 1.80 (0.97e3.33) 1
Stroke/TIA (Black-Meier et al., Eitel et al.) 2 1.3% (6/455) 1.8% (5/279) 0.59
Repeat ablation (Black-Meier et al., Eitel et al.) 2 17.1% (78/455) 8.6% (24/279) 0.001
HF hospitalization at 12 months (Black-Meier et al.) 1 6.0% (8/133) 10.3% (10/97) 0.23
Arrhythmia hospitalization at 12 months (Black-Meier et al.) 1 14.3% (19/133) 13.4% (13/97) 0.85
Non-fatal MI (Eitel et al.) 1 0% (0/322) 0.5% (1/182) 0.20
Major bleeding (Eitel et al.) 1 0.3% (1/322) 1.6% (3/182) 0.11
HFpEF ¼ heart failure with preserved ejection fraction, HFrEF ¼ heart failure with reduced ejection fraction, HR ¼ hazard ratio, TIA ¼ transient ischaemic attack, HF ¼ heart
failure, MI ¼ myocardial infarction.
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findings. The substrate responsible for AF is usually due to changes
in structure and function of atria [25,26]. These can be secondary to
alterations in hemodynamics in heart failure patients or a conse-
quence of the cardiomyopathic process depending on the under-
lying etiology [27]. In particular, an increase in left atrial volume
and pressure which increases left ventricular end-diastolic
dimension and pressure and mitral regurgitation can result in
fibrosis and remodelling that directly results in the development of
AF [28]. The amount of remodelling is directly related to the
duration of AF, i.e. Paroxysmal vs persistent; and ongoing hemo-
dynamic strain due to HFpEF or HFrEF. Moreover, the remodelling is
influenced by various comorbid conditions like hypertension, dia-
betes; and previous excessive smoking, excessive alcohol, raised
body weight, extremes of exercise [29,30]. However, there is min-
imal impact by type of heart failure on success or complication rate
after AF ablation, hospitalization and MACEs after ablation therapy.
Symptomatic patients suitable for AF ablation represents a small
portion of all the patients with AF as most patients with AF are
asymptomatic which makes it challenging to determine the true
prevalence of AF [31]. It is possible that operators may be selecting5
patients who are more likely to have successful ablations. Among
the factors identified as risk factors for recurrence of AF after
ablation, two key factors are left atrial size and stiffness [11]. While
both HFpEF and HFrEFmay result in both types of left atrial changes
the fact that not these changes are not more prevalent in one of the
heart failure groups may explainwhy patients with both HFpEF and
HFrEF may stand to equally benefit from ablation as shown in this
study. In addition, there may be selection of patients for ablation
procedures who are of lower risk such as patients who are young
and less comorbid because in the elderly population it may be safer
to rate control and anticoagulated patients with medications.
We found that patients with HFpEF have more repeat ablation
and arrhythmic hospitalizations compared to HFrEF. One explana-
tion for this difference is due to larger left atrial size and more
fibrosis due to raised left ventricular end-diastolic pressure
continue to degenerate atrial substrate resulting in higher recur-
rence in HFpEF. Positive remodelling after the restoration of sinus
rhythm in HFrEF can be an explanation of the reduced rate of
recurrence after modifiable factor correction.
There are several limitations in this review. First, none of the
included studies are randomized trials, so the findings are at risk of
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the largest study included 521 patients. The second group of limi-
tations relate to heterogeneity in the studies, which includes
methodological differences in the study such as different defini-
tions for HFrEF, and the patient population including a mixture of
paroxysmal and persistent AF. Furthermore, while pulmonary vein
isolation is the standard ablation strategy as we had no restriction
on the type of ablation and procedural variables due to multiple
lines, complex fractionated atrial electrograms, or AV node abla-
tion. In addition, the differences in length of follow-up for AF
recurrence, lack of standardized definition of recurrence of
arrhythmia, the different cutoffs used for left ventricular ejection
fraction for heart failure definition are other limitations to this
metanalysis.
In conclusion, our review found that is no difference in AF
recurrence comparing HFrEF to HFpEF. However, there is some
evidence to suggest that patients with HFpEF are more likely to
have repeat ablation compared to HFrEF. While periprocedural
complications rates are similarly low for both HFpEF and HFrEF,
one-year mortality is greater in patients with HFrEF compared to
HFpEF.
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